Hideho Okada

Classification of current anticancer immunotherapies.

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.

Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity.

Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC).

Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy.

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.

Cellular immunotherapy for malignant gliomas.

Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine.

Is the immune response a friend or foe for viral therapy of glioma?

Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.

Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model.

Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment.

Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.

Immunotherapy of Primary Brain Tumors: Facts and Hopes.

Cell penetrating peptide functionalized perfluorocarbon nanoemulsions for targeted cell labeling and enhanced fluorine-19 MRI detection.

Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy.

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).

Tumor antigens in glioma.

T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.

Introduction to immunotherapy for brain tumor patients: challenges and future perspectives.

Considerations when treating high-grade pediatric glioma patients with immunotherapy.

Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade.

Current Advances in Immunotherapy for Glioblastoma.

Assessing Oximetry Response to Chimeric Antigen Receptor T-cell Therapy against Glioma with F MRI in a Murine Model.

SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma.

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.

IFN-γ- and IL-17-producing CD8 T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity.

Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.

The future of cancer immunotherapy for brain tumors: a collaborative workshop.

RASA2 ablation in T cells boosts antigen sensitivity and long-term function.

Magnetic Resonance Spectroscopy Metabolites as Biomarkers of Disease Status in Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) Treated with Glioma-Associated Antigen Peptide Vaccines.

Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch .

Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma.

Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective.

Challenges in the discovery of tumor-specific alternative splicing-derived cell-surface antigens in glioma.

IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma.

A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.

IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma.

Activating the dark genome to illuminate cancer vaccine targets.